December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Efficary and Safety of Latanoprost or Brimonidine in Patients with Ocular Hypertension or Primary Open Angle Glaucoma
Author Affiliations & Notes
  • CB CamrasUnited States Latanoprost-Brimonidine Study Group
    Ophthalmology Univ of Nebraska Med Center Omaha NE
  • Footnotes
    Commercial Relationships    C.B. Camras, Pharmacia F, C, R; Allergan F; Alcon F; Novartis F; Santen F.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1083. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      CB CamrasUnited States Latanoprost-Brimonidine Study Group; Efficary and Safety of Latanoprost or Brimonidine in Patients with Ocular Hypertension or Primary Open Angle Glaucoma . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1083.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To determine the relative efficacy and safety of latanoprost (LP) or brimonidine (BR). Methods: In a multicenter, randomized, examiner-masked, parallel study, patients with ocular hypertension or early primary open angle glaucoma received either LP 0.005% (n=152) once daily at 0800 hr or BR 0.2% (n=151) twice daily at 0800 and 2000 hrs for six months. Intraocular pressure (IOP) was measured at 0800, 1000, 1200, and 1600 hrs at baseline, and at 2 weeks, 3 months, and 6 months. Results: Comparing 6-month to baseline mean (± SD) diurnal IOP (24.5 ± 3.1 mmHg for LP and 24.8 ± 2.7 mmHg for BR), the IOP reduction was significantly (p<0.001) greater for LP (-5.7 ± 3.3 mmHg, -23 ± 12%) than for BR (-3.3 ± 3.2 mmHg, -13 ± 12%). Patients achieving mean diurnal IOP reductions of 10%, 25%, and 40% were 87%, 44%, and 8% for LP, and 66%, 13%, and 0% for BR, respectively. Adverse events severe enough to result in termination from the study included (LP vs BR, respectively): conjunctival allergic reaction, papillary reaction, irritation, redness, eyelid dermatitis, or eyelid edema (1% vs 17%); fatigue, dizziness, somnolence, depression, mental impairment, or headache (0% vs 6%); dry mouth (0% vs 1%). Conclusion: Compared with brimonidine, latanoprost is a more effective and better tolerated medication for the treatment of elevated IOP.

Keywords: 357 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 514 pharmacology • 392 eicosanoids 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.